



## PRESS RELEASE

### PAION'S PARTNER LUNDBECK PRESENTED DATA FROM A POST-HOC ANALYSIS USING DESMOTEPLASE IN ISCHAEMIC STROKE

Aachen (Germany), 25 February 2010 – The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) informs that its licensing partner H. Lundbeck A/S had presented data from a post-hoc analysis using Desmoteplase in ischaemic stroke at the International Stroke Conference in San Antonio, Texas.

The findings from the post-hoc analysis of the DIAS-2 trial performed by PAION provided the basis for the design of the currently ongoing clinical phase III programme (DIAS-3 and DIAS-4 studies). DIAS-3 and DIAS-4 are randomized, double-blind, placebo-controlled, multinational phase III twin trials, aiming to enrol 800 patients with acute stroke. Estimated study completion is 2011.

You will find further information in the Lundbeck press release published today under [www.lundbeck.com](http://www.lundbeck.com).

###

#### **About Desmoteplase**

Desmoteplase, the most fibrin-specific plasminogen activator known today, is a genetically engineered version of a clot-dissolving protein found in the saliva of the vampire bat *Desmodus rotundus*. It has received fast-track designation from the U.S. Food and Drug Administration for the indication of acute ischemic stroke.

Patients in an earlier clinical phase III trial with Desmoteplase were eligible for treatment only in case of a detectable penumbra (insufficiently perfused but still salvageable tissue area around the primary location of stroke) of at least 20% of the affected area and were not screened for presence of vessel occlusion in the larger brain arteries using angiography. The data from the re-analysis of angiographs from these patients demonstrated that, in contrast to the phase II studies, 70% of the patients in the phase III trial lacked visible vessel occlusion before treatment.

When analysing patient subgroups using presence of vessel occlusion as treatment criteria, a reduced response rate on the placebo group and a positive effect of Desmoteplase versus placebo is observed, however not statistically significant due to the small sample size. Additionally, pooled results from the clinical phase II and III studies show statistically significant efficacy in favour of Desmoteplase if patients without visible occlusions in the large brain arteries are excluded. These novel findings are encouraging and support continued clinical investigation in patients with acute ischemic stroke within 3 to 9 hours after onset of stroke symptoms.

Lundbeck has obtained worldwide rights to Desmoteplase from PAION AG in Germany. PAION has been supporting in the planning of the new trials.

### **About stroke**

Stroke is the third leading cause of death in the industrialised world and a leading cause of serious, long-term disability. In the US alone, approximately 700,000 people suffer an ischemic stroke each year, and around 8-12% of them die within 30 days. For the US, the American Heart Association estimates the financial burden of stroke due to in-hospital costs, long-term care programmes and productivity losses to approximately USD 66 billion in 2008.

### **About PAION**

PAION is a biopharmaceutical company headquartered in Aachen, Germany and has a second site in Cambridge, UK. The company is specialized in developing and commercializing innovative drugs for the hospital-based treatment in indications for which there is a substantial unmet medical need. PAION has a "Search & Develop" business model, which is based on its core expertise in drug development. Where appropriate, particularly during the late stages of the clinical development, PAION seeks to collaborate with experienced partners.

### **Contact**

Ralf Penner  
Director Investor Relations & Public Relations  
PAION AG  
Martinstrasse 10-12  
52062 Aachen – Germany  
Phone: +49 241 4453-152  
E-mail: [r.penner@paion.com](mailto:r.penner@paion.com)  
[www.paion.com](http://www.paion.com)

### **Disclaimer:**

This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments.